New drug CAN016 takes on advanced cancers in first human trial

NCT ID NCT07664150

Recruiting now Disease control Sponsor: Canwell Biotech Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a new drug, CAN016, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, and second, seeing if the drug shrinks tumors. About 90 participants will receive CAN016 every three weeks. The goal is to check safety and whether the drug can control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAN016 (a drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early first-in-human study with only 90 participants, so the drug may not be effective or could cause unexpected side effects. Success in this small group may not apply to a broader population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cancer Hospital Chinese Academy Of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.